Viracta Therapeutics, Inc. (VIRX) Misses Q2 EPS by 3c

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ennis (EBF) Reports In-Line Q1 EPS
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth